More recently, novel xyloside-derived compounds with potential to be used in therapy for glioblastoma were identified due to their ability of impairing endogenous GAG biosynthesis by binding to XYLT1 and β4GAL T7 active sites, and consequently decreasing glioblastoma cell viability (135). The gene discussed is XYLT1; the disease is glioblastoma.